Novartis shares fell 2.7% on Thursday 19 November after the Swiss drugmaker set a goal of 5% a year sales growth from 2026 to 2031, the bottom of the 5% to 6% range it promised a year ago. The trimmed target outweighed $4bn of upgrades to the peak-sales forecasts for three of its fastest-growing medicines and a pledge to lift its core operating margin back above 40% by 2029.
Novartis investor day in numbers
- 5% a year sales growth target at constant currencies, 2026 to 2031
- $18bn combined peak sales now forecast for Kesimpta, Scemblix and Leqvio, up from $14bn
- CHF 127.94 share price after a 2.7% fall at Thursday's open
What Novartis promised investors in London
The new targets came out on Thursday in Basel, ahead of the annual Meet Novartis Management event in London. Net sales are expected to grow 5% a year at constant currencies, a measure that strips out exchange-rate swings. The core operating income margin, the share of sales left as operating profit before one-off items, is "on track to return to 40%+ by 2029", the company said.
On paper the change is small. A year ago Novartis guided to 5% to 6% annual growth for 2025 to 2030, according to a Reuters report carried by cash.ch. The window has moved on by a year and the top of the range has gone.
For 2026 itself, management confirmed its forecast of sales growth in the low single digits, with core operating income flat or up by a low single-digit percentage, cash.ch reported.
Novartis: share price, chart and news

Why Novartis shares fell despite higher drug forecasts
The shares dropped 2.7% at the open to CHF 127.94, cash.ch reported, and dpa-AFX listed Novartis as the weakest stock in Switzerland's blue-chip SMI index. At 16:15 CET cash.ch's live quote still showed them down 2.6%, at CHF 128.06.
They fell from a height. Novartis closed at a record CHF 135.76 on Monday, and the stock is still up about 16% this year. That recovery followed its worst day on record in September, when del-desiran, a drug from its $12bn takeover of Avidity Biosciences, failed a late-stage trial and the heart drug pelacarsen also disappointed. At times the setbacks wiped almost $30bn off the company's market value, Reuters reported, and they led to a $1.9bn writedown in its third-quarter results in October.
Portfolio manager Daniel Bolanowski said the selloff reflected an "absence of anything revolutionary" in the update, according to PharmExec. Zürcher Kantonalbank noted that the new sales goal still sits above the consensus, which PharmExec put at about 4.5% a year, but said the higher product targets offered little upside. Its analyst Urban Fritsche called Novartis a "show me" story that depends on good trial data.
Kesimpta, Scemblix and Leqvio get bigger sales targets
Peak sales are the most a medicine is expected to earn in its best year. Novartis lifted that figure for three drugs:
| Drug | Used for | Old peak sales goal | New peak sales goal |
|---|---|---|---|
| Kesimpta | Multiple sclerosis | $6bn | $8bn |
| Scemblix | Chronic myeloid leukaemia | $4bn | $5bn |
| Leqvio | Lowering cholesterol | $4bn | $5bn |
Chief executive Vas Narasimhan gave the reasons, dpa-AFX reported. Kesimpta is winning market share outside the US and still growing at home. Scemblix can now be used as a first treatment in the US. Leqvio, a cholesterol injection, is seeing strong demand in the US and Asia, above all in China and Japan.
The pill Rhapsido, also known as remibrutinib, had already had its target raised to $8bn across two forms of chronic hives and relapsing multiple sclerosis, the disease in which it beat a rival drug in two late-stage trials. Novartis now counts nine medicines on sale, Kisqali and Cosentyx among them, with peak-sales potential of $3bn to $10bn each.
How patent expiries shape the Novartis outlook
The shadow over all this is loss of exclusivity: patents run out and cheaper copies arrive. "In 2026 we expect to grow through the largest loss-of-exclusivity impact in our history," Narasimhan said in the company's statement.
The heart failure drug Entresto, the leukaemia drug Tasigna and the blood platelet drug Promacta are the main blockbusters affected, dpa-AFX reported. Entresto alone is expected to lose roughly $4bn of sales this year, according to PharmExec.
The next cliff explains the trimmed target. Narasimhan pointed to the expected expiry of the US patent on the breast cancer drug Kisqali in the second half of 2031, after which Novartis expects growing competition from copies, dpa-AFX reported.
What comes next for Novartis and its pipeline
Novartis expects more than 35 trial readouts through 2031 that could support filings for approval, and ten late-stage candidates carry multibillion-dollar peak-sales guidance. Among the drugs highlighted in London were the myelofibrosis treatment pelabresib, the lupus candidate ianalumab and two muscular dystrophy drugs from the Avidity deal, del-brax and del-zota.
"Most of the growth beyond 2031 will come from internally developed medicines," Narasimhan said at the event, PharmExec reported. The plan assumes no large acquisitions; the focus stays on deals and licences worth less than $2bn, according to dpa-AFX. Jefferies analyst Michael Leuchten said the upgrades noticeably strengthened the growth outlook, but that the presentation left open how likely the newer drugs are to succeed.
Investors showed similar doubts at Novo Nordisk's capital markets day in September, when long-term blockbuster targets also failed to lift the shares. For Novartis, the next test is data: each late-stage readout will show whether 5% is a floor or a ceiling.
Why did Novartis shares fall today?
Novartis shares fell 2.7% at the open on Thursday 19 November 2026 after the company set a target of 5% annual sales growth for 2026 to 2031, the low end of its previous 5% to 6% goal.
What is Novartis's sales growth target to 2031?
Novartis expects net sales to grow 5% a year at constant currencies from 2026 to 2031.
Which Novartis drugs are losing patent protection?
Entresto, Tasigna and Promacta are the main blockbusters losing exclusivity, and Novartis expects the US patent on Kisqali to expire in the second half of 2031, according to chief executive Vas Narasimhan.
Sources
- Novartis: Novartis projects +5% cc sales CAGR through 2031 and sustained mid-single-digit growth over the long term
- cash.ch (Reuters): Novartis passt Wachstumsziel an, Aktie unter Druck
- dpa-AFX via AD HOC NEWS: Novartis dämpft Mittelfristziel leicht, Pipeline soll Wachstum bringen
- PharmExec: Novartis Trims Growth Target at Annual Management Day, Shares Slide
- pharmaphorum: Novartis raises forecasts for three key growth products








